Chapter 6: Antepartal Tests

The nurse serves as a critical educator, advocate, and support person, ensuring that pregnant individuals receive adequate information for informed decision-making while witnessing consent and providing procedural education. The chapter establishes a fundamental distinction between screening tests, which estimate risk of fetal abnormalities without providing definitive diagnosis, and diagnostic tests, which offer conclusive results regarding chromosomal or structural anomalies. Biophysical assessment methods, including standard and specialized ultrasound imaging, magnetic resonance imaging for complex anomalies, and Doppler flow studies for evaluating placental perfusion and detecting intrauterine growth restriction, provide visual and hemodynamic information about fetal development. Biochemical assessment through invasive procedures such as chorionic villus sampling in early gestation, amniocentesis during the second trimester, and fetal blood sampling enables direct analysis of fetal cells and chromosomes for genetic diagnosis. Maternal serum assays, including cell-free DNA screening, alpha-fetoprotein measurement, and multiple marker screening panels, identify pregnancies at increased risk for chromosomal abnormalities and neural tube defects through biochemical markers. Antenatal fetal surveillance techniques such as daily fetal movement counting, nonstress testing, vibroacoustic stimulation, contraction stress testing, amniotic fluid assessment, and biophysical profiling allow ongoing evaluation of fetal status to prevent adverse outcomes like stillbirth. Throughout these multiple testing modalities, nurses must navigate complex ethical considerations surrounding abnormal findings and support patient-centered decision-making with appropriate health literacy and nonjudgmental guidance as families face significant diagnostic and reproductive choices.